Amgen's 'Pointless' Biosimilar Pathway Suit Gets Axed
A New Jersey federal judge on Friday tossed an Amgen lawsuit aimed at compelling biosimilar makers to engage in talks over patent information, calling the suit "completely pointless" and an improper...To view the full article, register now.
Already a subscriber? Click here to view full article